Care For People, Cure Every Patient

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

PersonGen BioTherapeutics (Suzhou) Co. Ltd is a biotech company focusing on developing leading-edge cellular therapeutics. The company is committed to developing CAR-related therapeutic and analytical antibodies, novel CAR-T products, and allogeneic cellular therapies. We have a comprehensive pipeline of our products and the platform for developing iPSC-derived cellular therapies.

PersonGen.Anke Cellular Therapeutics Co., Ltd.

PersonGen-Anke Cellular Therapeutics Co., Ltd. is a subsidiary company and the manufacturing base of PersonGen BioTherapeutics. The company is equipped with the global-leading fully-automated, closed manufacturing system for cellular therapeutics. It also has the most advanced facilities for the manufacturing of clinical-grade DNA plasmids and lentiviruses. The company has developed fully validated manufacturing processes of CAR-T, allogeneic γδT and UCAR-γδT products.

Read More

Technology Platform

PersonGen BioTherapeutics is one of the first company in China focusing on the development of CAR-T and other cellular immunotherapies.
We are driven by our values “Care for People, Cure Every Patient”, and is committed to being the world leader on developing allogeneic cellular therapies against T-ALL and NKTCL.



创新突破 共赢未来 | 博生吉2023年度回顾


Conceptual Pilot Study, Patient Recruitment

Read More